NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.20 +0.82 (+1.05%) GOLD FUTURES
2,316.80 -7.40 (-0.32%) DOW
39,088.27 +204.01 (+0.52%) Bitcoin GBP
49,853.49 -656.19 (-1.30%)
Arbutus Biopharma Corp (I9DN.SG)
| Previous close | 2.5820 |
| Open | 2.5820 |
| Bid | 2.5560 x 200000 |
| Ask | 2.6460 x 200000 |
| Day's range | 2.5560 - 2.5820 |
| 52-week range | 1.5340 - 3.0000 |
| Volume | |
| Avg. volume | 103 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireArbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York: The Citizens JMP Life Sciences Conference: Fi
Insider MonkeyArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
Simply Wall St.Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma ( NASDAQ:ABUS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.53m (down 77% from 1Q...
